Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290628 · ClinicalTrials.gov registry record · NA
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
A NA study, sponsored by Masonic Cancer Center, University of Minnesota.
- Terminated
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT00290628 is a NA study that was terminated before completion, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 43 participants.
The verdict
NCT00290628, a NA study, was terminated before completion, sponsored by Masonic Cancer Center, University of Minnesota.
- TERMINATED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related or unrelated donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow to make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This clinical trial is studying how well donor umbilical cord blood transplant works in treating patients with hematologic cancer.
Interventions
- DRUG cyclophosphamide
- DRUG filgrastim
- DRUG busulfan
- DRUG cyclosporine
- DRUG anti-thymocyte globulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 1999-10 |
| Est. Completion | 2007-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00290628
The ClinicalTrials.gov registry entry for NCT00290628 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00290628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00290628 about?
NCT00290628 is a clinical study titled "Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer". RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related or unrelated donor, that do...
What is the current status of trial NCT00290628?
This trial is currently terminated. It is a NA study. The enrollment target is 43 participants. The study started on 1999-10. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00290628?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (DRUG), busulfan (DRUG), cyclosporine (DRUG), anti-thymocyte globulin (DRUG).
Who is sponsoring clinical trial NCT00290628?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.